Bind Research
Our Research
Many incurable diseases involve biomolecules called ‘disordered proteins’ – considered ‘undruggable’ by the mainstream pharmaceutical industry.
These disordered proteins continuously change their three-dimensional shapes and lack long-lived sites with which drug-molecules can interact. Our mission is to make disordered proteins druggable. We are screening millions of disordered protein/drug-molecule pairs to learn the rules of drugging disordered proteins.
Our Expertise
Building on our expertise and working with academic and industrial partners, we are leveraging cutting-edge biology, engineering, and AI to deliver new drugs and tools.
We are building comprehensive datasets of disordered protein-drug interactions to create public assets to fuel AI models and accelerate the discovery process. To accomplish this in a manner for maximum societal benefit, we have established a Focused Research Organisation (FRO), a fully-independent not-for-profit entity dedicated to this goal.
Bind Research is joining the buzzing Cambridge scene! We have opened a satellite lab within the Milner Bio-Incubator at the Milner Therapeutics Institute in Cambridge. The Milner was set up to bridge academia and industry in drug discovery, bringing together its own research programme in functional genomics and target discovery with a consortium of pharma […]
20 May 2026
We’re happy to share that Rashik Aryal, MSc is the latest addition to the Bind Research family! Rashik joins us as Research Assistant, bringing a genuinely multidisciplinary background, from clinical diagnostics to genetic engineering to early-stage protein research. Rashik will be supporting Bind across protein expression and characterisation workflows, while also helping us develop rigorous, […]
1 May 2026
We’re delighted to welcome Mark Murcko, Ph.D. to the Board of Bind Research and our Lead Scientific Advisor. Mark joins Tom Kalil, who was recently appointed Interim Chair of the Board. Tom is CEO of Renaissance Philanthropy, an organisation that has already played a vital role in Bind’s establishment. Mark brings to Bind a deep […]
28 Apr 2026
Do you have a background in a highly technical field and a passion for disordered proteins and drug discovery?
Interested in working with Bind to make disordered proteins druggable? Reach out!
Find out more
We are onboarding partners in charities, the pharmaceutical industry, technology, academia and more. Please reach out!
Find out more